Transphorm Ships Over Half a Million GaN Power Devices for Multi-kilowatt Class Applications
7.11.2019 16:00:00 EET | Business Wire | Press release
Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified 650 V gallium nitride (GaN) semiconductors—disclosed that it has shipped more than 500 thousand high voltage GaN FETs. The company hit this milestone as customers continue to adopt its high quality-high reliability GaN platform.
High Voltage GaN Adoption
Customers in the broad industrial, infrastructure and IT, and PC Gaming markets have publicly announced in-production devices built with Transphorm’s GaN technology. They illustrate the rising confidence in GaN solutions that are projected to be an attractive market.
In fact, industry analyst firm IHS Markit Technology, now a part of Informa Tech, forecasts the total GaN power discrete, module, and system IC revenues to reach $1.2 billion by 2028. Approximately $750 million of those revenues (almost two-thirds of the total market) will be driven by high voltage GaN solutions.1
“We came to market with the most robust, two-chip normally-off device at a time when the industry was more familiar with single-chip normally-off Silicon MOSFETs,” said Primit Parikh, Co-founder and COO, Transphorm. “As proven by our public momentum and also that of other reputable manufacturers like Power Integrations in the consumer adapter space, the two-chip normally-off GaN solution is the most practical high voltage GaN FET design today. In fact, it’s this design that enables Transphorm’s GaN to deliver high performance with strong robustness, which has led to more than 5 billion hours (with <2 FIT) of field reliability data to date.”
Transphorm’s adoption success continues to be driven largely by the Quality and Reliability (Q+R) of its products. This Q+R is backed by the company’s robust normally-off GaN platform, strong control of its epitaxial process, and manufacturing capability—which is well-positioned to meet the volume and quality requirements of various cross-industry markets from consumer adapters to automotive. Together, these elements enable the company to produce GaN FETs that offer unparalleled reliability, designability, drivability, and reproducibility.
“Following our success in the core higher power markets targeted by GaN, we’re also working with customers in fast growing markets that are underserved by Silicon such as consumer adapters and set-top boxes,” said Philip Zuk, VP of Worldwide Technical Marketing and North American Sales, Transphorm. “Consider that the majority of products we’ve shipped to date were targeted for higher power applications. Those 500 thousand-plus 650V FETs equate to more than 4 million lower power (sub 100 Watts) FETs, demonstrating our volume production capabilities.”
Field Reliability
A year ago, Transphorm released the first complete set of validation data for high voltage GaN power semiconductors. Today, the company formally released its latest field reliability data. With more than five billion hours in the field, Transphorm’s GaN technology currently has a <2.0 FIT rate at <19.8 PPM per year. For more information on device Quality + Reliability, visit the company’s Q+R webpage.
Welcome to the GaN Revolution!
Transphorm designs and manufactures the highest performance, highest reliability 650 V and 900 V GaN semiconductors for high-voltage power conversion applications. Holding the largest IP portfolio (1000+ issued and pending patents worldwide), Transphorm produces the industry’s first JEDEC and AEC-Q101 qualified GaN FETs. This is due to a vertically-integrated business approach, which allows for innovation at every development stage: design, fabrication, device, and application support. Website: www.transphormusa.com Twitter: @transphormusa
1 SiC & GaN Power Semiconductors Report, IHS Markit, May 2019
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191107005291/en/
Contact information
Heather Ailara
211 Communications
heather@211comms.com
P: +1.973.567.6040
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 16:00:00 EEST | Press release
Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software. "Almost every organization we speak to is trying to get its data ready for AI, and most of them are realizing that the hard part is not the model, it is the da
Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 16:00:00 EEST | Press release
Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim2.9.2026 15:00:00 EEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 15:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha ® Portfolio2.9.2026 14:37:00 EEST | Press release
Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructions for Use across the saypha® portfolio reflects our focus on practical digital solutions that support healthcare professionals and align with evolving regulatory requi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
